Type 2 Diabetes
Conditions
Brief summary
The purpose of this study is to evaluate the relative bioavailability of the new formulation of HRS9531 injection between the original formulation of HRS9531 injection.
Interventions
DRUGHRS9531
Receive a single dose of HRS9531 of original formulation.
Sponsors
Fujian Shengdi Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This study is a single-dose, parallel design trial, consisting of two parallel groups: a reference formulation group (R: original formulation) and a test formulation group (T: new formulation). Both R and T groups receive a same dose of HRS9531.
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Ability to understand the trial procedures and possible adverse events, be able and willing to provide a written informed consent; 2. Age 18-45 years on the date of signing informed consent (inclusive); 3. Body weight ≥50 kg for male and 45 kg for female, body mass index (BMI) within the range of 19.0-26.0 kg/m2 (inclusive); 4. Subjects with good general health, no clinically significant abnormalities.
Exclusion criteria
1. With previous major organ diseases, including but not limited to neuropsychiatric, cardiovascular, digestive, respiratory, urinary, endocrine, blood, immune and other diseases, are judged by researchers to be unsuitable for the study; 2. Had a severe trauma or major surgery within 6 months prior to screening, planned to undergo surgery during the trial period; 3. Participants in clinical trials of any drug or medical device in the 3 months prior to screening; 4. Blood donation history or blood loss ≥400 mL within 3 month or ≥200 mL within 1 month before screening, or received blood transfusion within 3 months; 5. Allergic constitution includes severe drug allergy or history of drug allergy; 6. Hepatitis B surface antigen (HBsAg), HIV antibody detection, hepatitis C virus antibody (HCVAb), treponema pallidum specific antibody detection, positive; 7. Breast-feeding women; 8. The investigator considers that the subject has any other factors that would make it inappropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area Under the Concentration versus time curve (AUC) of HRS953 | Start of treatment up to Day 43 |
| Maximum Concentration (Cmax) of HRS9531 | Start of Treatment up to Day 43 |
| Calculate the ratio of bioavailability between the new formulation and original formulation of HRS9531 according to the equation F (relative bioavailability) =AUCT·DR/AUCR·DT×100% | Start of Treatment up to Day 43 |
Secondary
| Measure | Time frame |
|---|---|
| Apparent volume of distribution (VzF) | Start of Treatment up to Day 43 |
| Time to maximum concentration (Tmax) | Start of Treatment up to Day 43 |
| Incidence and severity of adverse events | Screening period up to Day 43 |
| Apparent terminal half-life (t1/2) | Start of Treatment up to Day 43 |
| Clearance (CL/F) | Start of Treatment up to Day 43 |
Countries
China
Outcome results
None listed